eslicarbazepine acetate + warfarin

The combination of eslicarbazepine acetate and warfarin represents a drug interaction rather than a single medication. Eslicarbazepine acetate is an antiepileptic drug used for treating partial-onset seizures, while warfarin is an anticoagulant used to prevent blood clots. Studies have shown that eslicarbazepine acetate affects warfarin's pharmacokinetics. When eslicarbazepine acetate 1200 mg once daily was co-administered with warfarin, it caused a small but statistically significant reduction (23%) in systemic exposure to S-warfarin[1][3]. However, this interaction did not produce clinically relevant changes in the International Normalized Ratio (INR), which is used to monitor warfarin's anticoagulant effect[1][3]. The mechanism behind this interaction likely involves eslicarbazepine acetate's enzyme-inducing properties. Eslicarbazepine acetate is a weaker enzyme inducer than carbamazepine (another antiepileptic in the same family), but it still has the potential to increase the metabolism of warfarin[2][3][4]. For patients taking both medications, healthcare providers may need to monitor INR values carefully, especially when starting eslicarbazepine acetate treatment in patients already stabilized on warfarin[3]. ## Detailed Information **Canonical name**: eslicarbazepine acetate + warfarin **Code names**: [] **Brand names**: [] **Other names**: [] **Description**: This is a combination of two medications that have a known drug interaction. Eslicarbazepine acetate is a voltage-gated sodium channel blocker used for treating partial-onset seizures. Warfarin is an anticoagulant used to prevent blood clots. When co-administered, eslicarbazepine acetate can reduce S-warfarin levels by approximately 23%, though this doesn't significantly affect coagulation as measured by INR.